Zomedica Revenue Growth Rates (ZOMDF), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Zomedica Corp   (NONE: ZOMDF)
 

ZOMDF's Revenue Growth by Quarter and Year

Zomedica 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZOMDF Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 9.51
1st Quarter March 8.48
FY 17.99

ZOMDFs Annual Revenue
Zomedica 's Revenue in the fiscal year 2025 $ 31.68 millions
Zomedica 's Revenue in the fiscal year 2024 $ 27.09 millions
Zomedica 's Revenue in the fiscal year 2023 $ 24.32 millions
Zomedica 's Revenue in the fiscal year 2022 $ 18.93 millions
Zomedica 's Revenue in the fiscal year 2020 $ -0.03 millions




ZOMDF Revenue second quarter 2026 Y/Y Growth Comment
Zomedica Corp reported Revenue improvement of 36.67% year on year in the second quarter 2026, to $ 9.51 millions, this is lower than Zomedica Corp 's recent average Revenue surge of 2617.33%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 101 other companies have achieved higher Revenue growth. While Zomedica Corp ' s Revenue rise of 36.67% ranks overall at the positon no. 1974 in the second quarter 2026.


ZOMDF Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 9.63 % 13.29 % 36.85 %
3rd Quarter September - 22.77 % 13.06 % 12.13 %
2nd Quarter June 36.67 % 29.85 % 6.14 % 18.82 %
1st Quarter March 32.29 % 4.74 % 11.68 % 46.13 %
FY   - 15.47 % 11.39 % -

Financial Statements
Zomedica 's second quarter 2026 Revenue $ 9.51 millions ZOMDF's Income Statement
Zomedica 's second quarter 2025 Revenue $ 6.96 millions Quarterly ZOMDF's Income Statement


ZOMDF Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 40.73 % 57.59 % 57.28 %
3rd Quarter September - 6.9 % 13.06 % 6.14 %
2nd Quarter June 12.17 % 8.58 % -12.42 % -7.85 %
1st Quarter March -19.01 % -32.88 % -27.4 % -11.04 %
FY (Year on Year)   - 15.47 % 11.39 % -


Back to ZOMDF Growth rate Comparisons >> Back to ZOMDF Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #305
Overall #1974

Revenue Y/Y Growth Statistics
High Average Low
41049.97 % 2617.33 % 9.71 %
(Sep 30 2022)   (Mar 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #102
Healthcare Sector #305
Overall #1974
Revenue Y/Y Growth Statistics
High Average Low
41049.97 % 2617.33 % 9.71 %
(Sep 30 2022)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Zomedica 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18025.58 % 867.55 % -32.9 %
(Dec 31 2021)  


ZOMDF's II. Quarter Q/Q Revenue Comment
Zomedica Corp achieved in the II. Quarter 2026 below company average Revenue rise of 12.17% quarter on quarter, to $ 9.51 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 8.58% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Zomedica 's Revenue growth quarter on quarter, overall rank is 731.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #121
Overall #731
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #53
Healthcare Sector #121
Overall #731
Revenue Q/Q Growth Statistics
High Average Low
18025.58 % 867.55 % -32.9 %
(Dec 31 2021)  


ZOMDF's II. Quarter Q/Q Revenue Comment
Zomedica Corp achieved in the II. Quarter 2026 below company average Revenue rise of 12.17% quarter on quarter, to $ 9.51 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 8.58% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Zomedica 's Revenue growth quarter on quarter, overall rank is 731.


Zomedica 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 35.90 $ 33.36 $ 31.28 $ 30.36 $ 28.98
Y / Y Revenue Growth (TTM) 23.89 % 21.84 % 15.47 % 16.91 % 14.69 %
Year on Year Revenue Growth Overall Ranking # 1134 # 1053 # 0 # 480 # 469
Seqeuential Revenue Change (TTM) 7.64 % 6.64 % 3.04 % 4.75 % 5.85 %
Seq. Revenue Growth (TTM) Overall Ranking # 788 # 1240 # 903 # 982 # 1289


Cumulative Revenue growth Comment
Although Zomedica 's Annual Revenue growth year on year were below company's average 2617.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.89% year on year, from 21.84% in Mar 31 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1053 to 1134.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 211
Overall # 1134

Revenue TTM Y/Y Growth Statistics
High Average Low
41049.97 %
 2617.33 %
9.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 305
S&P 500 # 1979
Cumulative Revenue growth Comment
Although Zomedica 's Annual Revenue growth year on year were below company's average 2617.33% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 23.89% year on year, from 21.84% in Mar 31 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1053 to 1134.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 211
Overall # 1134

Revenue TTM Y/Y Growth Statistics
High Average Low
41049.97 %
2617.33 %
9.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 102
Sector # 305
S&P 500 # 1979




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZOMDF's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Precision Optics Corporation Inc 41.95%$ 41.951 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions


About Zomedica Revenue Growth Rates (ZOMDF), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zomedica Corp (CIK 1684144).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-091075
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zomedica Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.